- Home
- TGHL vs XAIR Comparison
TGHL vs XAIR Comparison
Compare TGHL & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | XAIR |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.5M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | TGHL | XAIR |
|---|---|---|
| Price | $0.36 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 81.2K | ★ 136.6K |
| Earning Date | 05-01-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $94,130.00 | ★ $5,802,000.00 |
| Revenue This Year | N/A | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.29 | $0.67 |
| 52 Week High | $4.25 | $10.40 |
Technical Indicators
Market Signals| Indicator | TGHL | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 20.43 |
| Support Level | N/A | $0.67 |
| Resistance Level | N/A | $1.31 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 5.35 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.